Skip to main content

CORRECTION article

Front. Pharmacol., 23 September 2022
Sec. Obstetric and Pediatric Pharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.972477

Corrigendum: Insulin treatment of hypertriglyceridemia during pregnancy

This article is a correction to:

  1. Insulin Treatment of Hypertriglyceridemia During Pregnancy

    1. Read original article
De-cui ChengDe-cui ChengYao SuYao SuFeifei LiFeifei LiXianming Xu Xianming Xu*
  • Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China

A Corrigendum on
Insulin treatment of hypertriglyceridemia during pregnancy

by Cheng D-c Su Y, Li F and Xu X (2022). Front. Pharmacol. 12:785756. doi: 10.3389/fphar.2021.785756

In the published article, there was an error in the Affiliation. Instead of “Department of Obstetrics and Gynecology, Jiao Tong University School of Medicine, Shanghai, China,” it should be “Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China.”

Additionally, a correction has been made to Methods section, paragraph 1. The last sentence previously stated “This research was registered with the Chinese Clinical Trial Registry (ChiCTR2000036575).” However the correct sentence is “This research was funded by the Chinese Clinical Trial Registry (ChiCTR2000036575).” The Conflict of Interest statement has also been updated to reflect this.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Conflict of interest

This study received funding from Chinese Clinical Trial Registry (ChiCTR2000036575). The funder had the following involvement with the study: service charge of postgraduates collecting data and also for publishing fee.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: insulin, hypertriacylglycerolemia, pregnancy, hypercholesterolemia, fetus

Citation: Cheng D-c, Su Y, Li F and Xu X (2022) Corrigendum: Insulin treatment of hypertriglyceridemia during pregnancy. Front. Pharmacol. 13:972477. doi: 10.3389/fphar.2022.972477

Received: 18 June 2022; Accepted: 15 August 2022;
Published: 23 September 2022.

Edited by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Cheng, Su, Li and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xianming Xu, xuxm11@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.